Clinical Trial Update: Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 trial update for ART5803 assessing safety and pharmacokinetics after IVIG in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis

Drugs mentioned

• ART5803

Snippet

Sponsor: Arialys Therapeutics | Conditions: Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder) | Phase 1 | Status: ACTIVE_NOT_RECRUITING